Huminsulin Basal Kwikpen Lilly (Insulin Human (Rdna))

Huminsulin Basal Kwikpen Lilly is indicated for the management of chronic hyperglycaemia in diabetes. It is used as part of a comprehensive diabetes treatment plan that includes diet, exercise, and other glucose‑lowering agents.

• Basal insulin therapy for adults with type 1 diabetes mellitus.
• Basal insulin therapy for adults with type 2 diabetes mellitus.
• Adjunct to rapid‑acting insulin in multiple daily injection regimens.
• Replacement therapy when endogenous insulin production is insufficient.
• Support for patients transitioning from other basal insulin formulations.

• Huminsulin Basal Kwikpen Lilly contains insulin human, which binds to insulin receptors on cell membranes, activating the receptor's intrinsic tyrosine kinase activity. This triggers intracellular signaling cascades that promote glucose transporter translocation, enhancing cellular glucose uptake, and suppresses hepatic gluconeogenesis, thereby lowering blood glucose concentrations over an extended period.

Adverse reactions may occur with any insulin therapy. They are categorized by frequency and severity.

Common

• Injection site redness, swelling, or itching.
• Low blood sugar (hypoglycaemia) symptoms such as shakiness, sweating, or dizziness.
• Weight gain.
• Lipodystrophy at the injection site.

Serious

• Severe hypoglycaemia requiring assistance.
• Allergic reactions including rash, urticaria, or anaphylaxis.
• Edema or fluid retention.
• Hypersensitivity leading to bronchospasm.

Huminsulin Basal Kwikpen Lilly should be used with careful monitoring and awareness of potential risks.

• Assess blood glucose regularly to adjust dose and avoid hypoglycaemia.
• Use a different injection site each time to reduce lipodystrophy.
• Patients with renal or hepatic impairment may require dose adjustments.
• Pregnancy and lactation status should be evaluated; safety data are limited.
• Store the pen according to manufacturer instructions to maintain potency.
• Discontinue use if signs of allergic reaction develop.

Certain medications and substances can affect the action of Huminsulin Basal Kwikpen Lilly.

Avoid

• Concurrent use of other insulin products without dose adjustment.
• High‑dose beta‑blockers that may mask hypoglycaemia symptoms.
• Alcohol excess, which can potentiate hypoglycaemia.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycaemia risk.
• Corticosteroids, which may raise blood glucose levels.
• Thyroid hormones, which can alter insulin requirements.
• Certain diuretics that affect electrolyte balance and glucose control.